• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by HilleVax Inc.

    7/22/24 9:02:05 PM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HLVX alert in real time by email
    SC 13G 1 j712243sc13g.htm

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    HilleVax, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

     

     

    43157M102

    (CUSIP Number)

     

     

     

    July 12, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 8 Pages 
     

     

    CUSIP No. 43157M102

     

    13G Page 2 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2

    Check the Appropriate Box if a Member of a Group*

    (a) ¨
    (
    b) x
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    4,712,954

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

      8

    Shared Dispositive Power

     

    4,712,954

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,712,954

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.5%

    12

    type of reporting person

     

    pN

     

     Page 2 of 8 Pages 
     

     

    CUSIP No. 43157M102

     

    13G Page 3 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2

    Check the Appropriate Box if a Member of a Group*

     

    (a) ¨
    (
    b) x
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    4,712,954

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

      8

    Shared Dispositive Power

     

    4,712,954

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,712,954

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.5%

    12

    type of reporting person

     

    OO

     

     Page 3 of 8 Pages 
     

     

    CUSIP No. 43157M102

     

    13G Page 4 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2

    Check the Appropriate Box if a Member of a Group*

     

    (a) ¨
    (
    b) x
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

     

    0

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    4,712,954

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

      8

    Shared Dispositive Power

     

    4,712,954

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    4,712,954

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.5%

    12

    type of reporting person

     

    IN

     

     Page 4 of 8 Pages 
     

     

    Item 1(a).Name of Issuer:

     

    HilleVax, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    321 Harrison Avenue, Boston, MA, 02118

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number 43157M102

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 4,712,954 of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 4,712,954 of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 4,712,954 of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 Pages 
     

     

    The percentages used herein are based on 49,720,943 shares of Common Stock outstanding as of May 6, 2024, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on May 9, 2024.

     

    (b)Percent of Class:

     

    Tang Capital Partners 9.5%
    Tang Capital Management 9.5%
    Kevin Tang 9.5%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Partners 4,712,954 shares
    Tang Capital Management 4,712,954 shares
    Kevin Tang 4,712,954 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 4,712,954 shares
    Tang Capital Management 4,712,954 shares
    Kevin Tang 4,712,954 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

     Page 6 of 8 Pages 
     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 Pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: July 22, 2024  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    TANG CAPITAL MANAGEMENT, LLC

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

     

    Page 8 of 8 Pages

     

     

     

     

    Get the next $HLVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLVX

    DatePrice TargetRatingAnalyst
    7/9/2024$28.00 → $2.00Outperform → Market Perform
    Leerink Partners
    7/9/2024$34.00 → $3.00Buy → Hold
    Stifel
    7/9/2024$28.00 → $2.00Buy → Neutral
    H.C. Wainwright
    7/8/2024Buy → Neutral
    Guggenheim
    7/8/2024$24.00 → $5.00Overweight → Neutral
    JP Morgan
    12/13/2023$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $HLVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Frazier Life Sciences X, L.P. bought $128,325 worth of shares (8,850 units at $14.50) (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/8/24 4:22:13 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mcloughlin Sean bought $21,225 worth of shares (1,250 units at $16.98) (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/1/24 4:08:42 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      $159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business development related activities and other strategic alternatives BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2025. First Quarter Financial Results As of March 31, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and

      5/8/25 7:00:30 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

      $171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2024. Full Year 2024 Financial Results As of December 31, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $171.4 mi

      3/28/25 5:00:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      11/14/24 9:36:33 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      11/14/24 9:00:08 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by HilleVax Inc.

      SC 13G - HilleVax, Inc. (0001888012) (Subject)

      7/22/24 9:02:05 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    SEC Filings

    See more
    • SEC Form 10-Q filed by HilleVax Inc.

      10-Q - HilleVax, Inc. (0001888012) (Filer)

      5/8/25 7:10:20 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HilleVax, Inc. (0001888012) (Filer)

      5/8/25 7:05:08 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13D filed by HilleVax Inc.

      SCHEDULE 13D - HilleVax, Inc. (0001888012) (Subject)

      5/2/25 4:15:10 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Financials

    Live finance-specific insights

    See more

    $HLVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

      BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details:Date:  Tuesday, September 6, 2022Time:  1:00 – 2:00 p.m. Eastern Daylight Time (EDT)Moderator:  Eric Joseph, Ph.D.HilleVax Participant:  Robert Hershberg, M.D., Ph.D.,

      9/1/22 5:18:14 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gerberding Julie L.

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:12 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Chu Shelley

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:15 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Hilleman Jeryl L

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:11 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Leadership Updates

    Live Leadership Updates

    See more
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

      Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r

      5/9/24 4:05:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

      BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.  Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Le

      1/18/24 7:00:00 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $HLVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HilleVax downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded HilleVax from Outperform to Market Perform and set a new price target of $2.00 from $28.00 previously

      7/9/24 9:48:14 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by Stifel with a new price target

      Stifel downgraded HilleVax from Buy to Hold and set a new price target of $3.00 from $34.00 previously

      7/9/24 7:46:22 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded HilleVax from Buy to Neutral and set a new price target of $2.00 from $28.00 previously

      7/9/24 7:46:01 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care